Log in to save to my catalogue

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capac...

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capac...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c3dacfdcee5044c4a6d220158af4b33c

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity

Publication information

Publisher

United States: American Society for Clinical Investigation

More information

Scope and Contents

Contents

The SARS-CoV-2 spike (S) glycoprotein is synthesized as a large precursor protein and must be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia virus Ankara (MVA) expressing native, full-length S protein (MVA-SARS-2-S) is currently under investigation as a candidate vaccine in phase I clinical studies. Initial result...

Alternative Titles

Full title

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_c3dacfdcee5044c4a6d220158af4b33c

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c3dacfdcee5044c4a6d220158af4b33c

Other Identifiers

ISSN

1558-8238,0021-9738

E-ISSN

1558-8238

DOI

10.1172/JCI159895

How to access this item